Patients and physicians are publicly shaming insurance companies on social media for the troublesome prior authorization process; HHS has awarded $1.4 billion in grants for the creation of new technologies and tools to prevent COVID-19 infection; Novo Nordisk has increased lobbying efforts to allow Medicare coverage of weight loss drugs.
Patients, Doctors Shame Insurers to Reverse Prior Authorization Denials
Patients and physicians have been publicly shaming insurance companies on social media to get drugs, tests, and treatments approved that were previously denied through the prior authorization process, according to KFF Health News. Patients explain that the rules create barriers that delay, or deny, access to treatment, and doctors note that these delays and denials mean death in some cases. Consequently, the federal government proposed prior authorization reform that would require insurance companies to be more transparent about denials and develop quicker response times; if finalized, these changes would be implemented in 2026. These reforms would exclude employer-sponsored health plans, meaning roughly half of the US population would not benefit from them.
HHS Awards $1.4 Billion for COVID-19 Countermeasures
HHS has awarded $1.4 billion in grants through its Administration for Strategic Preparedness and Response (ASPR) to fund the development of tools and technologies to protect against COVID-19, according to The Hill. HHS awarded the grants to pharmaceutical companies, nongovernmental organizations, and nonprofits as part of Project NextGen, an initiative led by ASPR to foster public-private partnerships to develop COVID-19 countermeasures. Most of the money that was awarded, $1 billion, went to 4 clinical trial partners of HHS’s Biomedical Advanced Research and Development Authority to support vaccine phase 2b clinical trials: Pharm-Olam LLC, ICON Government and Public Health Solutions Inc, Technical Resources International Inc, and Rho Federal Systems Inc. These were the first grants issued from NextGen of the $5 billion initial investment.
Novo Nordisk Boosts Lobbying for Obesity Drug Coverage
Novo Nordisk, creator of diabetes medication Ozempic and weight loss drug Wegovy, has increased its lobbying efforts in the past 6 months to push Congress to pass a bill that would lift Medicare restrictions against weight management treatment coverage, according to The Hill. The pharma giant has hired 3 new lobbying firms in the past 3 months to focus solely on obesity and Medicare coverage of anti-obesity drugs. This comes after the implementation of a 2023 law that excluded weight-loss drugs from Medicare coverage. Consequently, Novo Nordisk is increasing its lobbying efforts for the passing of the Treat and Reduce Obesity Act as public demand increases for weight loss drugs and clinical trials suggest Wegovy reduces the risk of serious heart problems. The act would expand weight management medication coverage to qualifying Medicare beneficiaries.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More